Antimicrobial Susceptibility Profile of Pseudomonas aeruginosa Isolates in Egypt

Journal of Urology

Volumn 180, Issue 1, 2008, Pages 176-181

  Gad, Gamal F ^a   El Domany, Ramadan A ^b   Ashour, Hossam M ^c  

^a MINIA UNIVERSITY   (Egypt)

^b HELWAN UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

cross infection; drug resistance; infection control; microbial; Pseudomonas aeruginosa; urinary tract infections

Indexed keywords

AGAR; AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFALEXIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; NORFLOXACIN; OFLOXACIN; SULTAMICILLIN; TETRACYCLINE;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; EGYPT; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SKIN INFECTION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; EGYPT; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL; URINARY TRACT INFECTIONS;

EID: 44649098146     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.03.081     Document Type: Article

References (20)

1. Gaynes R., and Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41 (2005) 848
2. Flamm R.K., Weaver M.K., Thornsberry C., Jones M.E., Karlowsky J.A., and Sahm D.F. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 48 (2004) 2431
3. Gad G.F., El-Domany R.A., Zaki S., and Ashour H.M. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. J Antimicrob Chemother 60 (2007) 1010
4. Abd-El-Haleem D., Kheiralla Z.H., Zaki S., Rushdy A.A., and Abd-El-Rahiem W. Multiplex-PCR and PCR-RFLP assays to monitor water quality against pathogenic bacteria. J Environ Monit 5 (2003) 865
5. Yetkin G., Otlu B., Cicek A., Kuzucu C., and Durmaz R. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey. Am J Infect Control 34 (2006) 188
6. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections 1988. Z Arztl Fortbild (Jena) 85 (1991) 818
7. Hasan A.S., Nair D., Kaur J., Baweja G., Deb M., and Aggarwal P. Resistance patterns of urinary isolates in a tertiary Indian hospital. J Ayub Med Coll Abbottabad 19 (2007) 39
8. Danchaivijitr S., Dhiraputra C., Rongrungruang Y., Worajitr M., and Jintanothaitavorn D. Antimicrobial susceptibility of community and hospital acquired bacteria. J Med Assoc Thai 88 suppl. (2005) S14
9. Katosova L.K., Zorkin S.N., Alekhina V.M., Chashchina I.L., and Abramov K.S. Resistance of urinary tract infection pathogens and choice of antibacterial therapy in pediatric urologic practice. Antibiot Khimioter 49 (2004) 34
10. Gales A.C., Sader H.S., and Jones R.N. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 44 (2002) 289
11. Astal Z. Susceptibility patterns in Pseudomonas aeruginosa causing nosocomial infections. J Chemother 16 (2004) 264
12. Hancock R.E., and Speert D.P. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3 (2000) 247
13. Ray G.T., Baxter R., and DeLorenze G.N. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis 41 (2005) 441
14. Aubert G., Carricajo A., Vautrin A.C., Guyomarc'h S., Fonsale N., Page D., et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 59 (2005) 83
15. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470
16. Streit J.M., Jones R.N., Sader H.S., and Fritsche T.R. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 24 (2004) 111
17. Bratu S., Quale J., Cebular S., Heddurshetti R., and Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 24 (2005) 196
18. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388
19. Fluit A.C., Verhoef J., and Schmitz F.J. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY Participants. Eur J Clin Microbiol Infect Dis 19 (2000) 370
20. Rodriguez C.N., Molina N., Garcia A., Nino C.R., Rodriguez A.J., and Meijomil P. Comparative study of antimicrobial resistance of Pseudomonas aeruginosa strains isolated from urinary tract infection in patients from Caracas and Lima. Int J Antimicrob Agents 20 (2002) 476